Last close As at 05/08/2026
—
— 0.00 (0.00%)
Market capitalisation
—
Scandion Oncology has announced that the Phase Ib PANTAX trial has concluded and reached its primary endpoint. This study (n=22) evaluated SCO-101, the company’s lead asset, as an add-on therapy for patients with advanced pancreatic cancer (PC). SCO-101, in combination with the chemotherapy agents gemcitabine and nab-paclitaxel, demonstrated a favourable safety and tolerability profile and a maximum tolerated dose (MTD) was established at 200mg for six consecutive days every two weeks. Management has communicated that a more detailed analysis on the full data will be conducted in due course, before deciding the next steps for developing SCO-101 in this indication.
Written by
Scandion Oncology |
PANTAX Phase I trial meets primary endpoint |
Clinical update |
Pharma and biotech |
3 April 2023 |
Share price performance
Business description
Analysts
Scandion Oncology is a research client of Edison Investment Research Limited |
||||||||||||||||||||||||||||||||||||
Scandion Oncology has announced that the Phase Ib PANTAX trial has concluded and reached its primary endpoint. This study (n=22) evaluated SCO-101, the company’s lead asset, as an add-on therapy for patients with advanced pancreatic cancer (PC). SCO-101, in combination with the chemotherapy agents gemcitabine and nab-paclitaxel, demonstrated a favourable safety and tolerability profile and a maximum tolerated dose (MTD) was established at 200mg for six consecutive days every two weeks. Management has communicated that a more detailed analysis on the full data will be conducted in due course, before deciding the next steps for developing SCO-101 in this indication.
Year end |
Revenue |
PBT* (DKKm) |
EPS* |
DPS |
DPS |
Yield |
12/21 |
0.8 |
(57.2) |
(1.61) |
0.0 |
N/A |
N/A |
12/22 |
2.1 |
(82.2) |
(1.88) |
0.0 |
N/A |
N/A |
12/23e |
0.6 |
(65.3) |
(1.47) |
0.0 |
N/A |
N/A |
12/24e |
0.6 |
(69.4) |
(1.57) |
0.0 |
N/A |
N/A |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
There remains a significant unmet medical need for PC treatments, as this is a challenging indication accounting for 7% of all cancer deaths. SCO-101 is under development for multiple oncology indications, including the treatment of PC. SCO-101 is a first-in-class chemosensitizer, a type of therapeutic with potential to re-sensitise resistant cancer cells to treatment when used in combination with traditional chemotherapy agents. With the PC market estimated to be worth $3.2bn by 2028 (source: EvaluatePharma), we believe this represents a significant opportunity for Scandion.
The PANTAX Phase Ib trial was an open-label, dose-escalation study, investigating the use of SCO-101 in combination with gemcitabine and nab-paclitaxel for the first-line treatment of PC. The key endpoints for this study were safety and tolerability, for which there were early signs of encouragement with the extension to the trial’s dosing schedule and to identify the MTD. At end-March 2023, Scandion announced that the trial met these primary endpoints. A total of 22 patients with unresectable or metastatic PC were enrolled in this trial and an MTD was established at 200mg given for six consecutive days every two weeks. Management has communicated that a more detailed analysis will be conducted and published once the final data are available; after this, they will consider what the next steps will be for the clinical development of SCO-101 as an add-on treatment for PC.
SCO-101 is also being investigated in the Phase II CORIST trial in metastatic colorectal cancer (mCRC) and read-outs for this study are expected in Q323. We note that as SCO-101’s mechanism of action is the same in both mCRC and PC. While we caution against direct read-across from clinical trials, we believe the key secondary endpoints from these studies, such as objective response rate, progression-free survival and overall survival, may influence the company’s decisions about clinical development in both indications.
|
|
Research: Healthcare
OpGen’s FY22 update reflected a busy period for the company following the FY22 preliminary update in January 2023. Top-line performance continued to be affected by longer sales cycles, although the year was marked by traction across the company’s business units. Operating losses rose to $34.6m in FY22, affected by a $12.3m impairment recognized for goodwill and in-process R&D. The adjusted operating loss of $22.2m was an improvement over the FY21 figure of $23.1m, supported by tighter control of R&D and G&A expenses. We expect financing to be a strategic priority in Q223 given the expected cash runway to June 2023 and upcoming debt repayment of the European Investment Bank (EIB) loan (€3m plus interest payments due in June). We revise our estimates to reflect FY22 performance and management’s FY23 revenue guidance of $4–5m. Our valuation stands at $66.7m (vs $67.5m). Our per share valuation adjusts to $12.2/share, reflecting the 1:20 share consolidation.